Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab.

about

Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab.

Item

http://www.wikidata.org/entity/Q48026614

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Comparison of drug survival an ...... with etanercept or adalimumab.

@en

Comparison of drug survival an ...... with etanercept or adalimumab.

@nl

type

Item

label

Comparison of drug survival an ...... with etanercept or adalimumab.

@en

Comparison of drug survival an ...... with etanercept or adalimumab.

@nl

prefLabel

Comparison of drug survival an ...... with etanercept or adalimumab.

@en

Comparison of drug survival an ...... with etanercept or adalimumab.

@nl

P1476

Comparison of drug survival an ...... with etanercept or adalimumab.

@en

P2093

A F Marsman

http://www.w3.org/2001/XMLSchema#string

E L Kneepkens

http://www.w3.org/2001/XMLSchema#string

G Wolbink

http://www.w3.org/2001/XMLSchema#string

I E van der Horst-Bruinsma

http://www.w3.org/2001/XMLSchema#string

J C van Denderen

http://www.w3.org/2001/XMLSchema#string

J Ruwaard

http://www.w3.org/2001/XMLSchema#string

M J l'Ami

http://www.w3.org/2001/XMLSchema#string

M T Nurmohamed

http://www.w3.org/2001/XMLSchema#string

P2860

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.

Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis.

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.

Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab

Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis.

Randomized, placebo controlled and double-blind trials of efficacy and safety of adalimumab for treating ankylosing spondylitis: a meta-analysis.

Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.

P304

1-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/03009742.2017.1330419

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28745108

http://www.w3.org/2001/XMLSchema#string

P921

adalimumab